Dr. Amarpreet Singh Sawhney
Dr. Amarpreet Sawhney is the CEO of Instylla, a company focused on embolic therapies for hypervascular tumors and control of hemorrhage, of Rejoni, a company developing products for preventing intrauterine scar formation, and of Pramand LLC, a company focused on developing biosurgery products. He was previously the Founder and CEO of Ocular Therapeutix, Augmenix, Confluent Surgical, and the technology founder of Focal and Access Closure. Amar’s innovations are the subject of over 120 issued and pending patents in biomaterials and bio-surgery. His inventions include several “first of a kind” surgical sealants, spacers, and drugs to be approved by the FDA including ReSure Sealant and Dextenza for ophthalmology, DuraSeal for neurosurgery, FocalSeal for Lung surgery, Mynx for femoral puncture sealing, and SpaceOAR for prostate cancer radiotherapy. Amar and his partner Fred Khosravi have created Incept LLC, which provides a platform to support other healthcare entrepreneurs. Amar has been recognized by several awards including being named the “Champion of Change” by the Whitehouse and “Outstanding American by Choice” by the US Citizenship and Immigration Service. His companies and inventions have touched over 5 million patients and have created over 4000 jobs to date. He is a member of the National Academy of Sciences and a fellow of the American Institutes of Biomedical Engg. Amar holds an M.S. and a Ph.D. in Chemical Engineering from the University of Texas at Austin and a B. Tech. in Chemical Engineering from the Indian Institute of Technology, New Delhi.